Free Trial
LON:TRX

Tissue Regenix Group (TRX) Share Price, News & Analysis

Tissue Regenix Group logo
GBX 8.74 -0.26 (-2.89%)
As of 03:33 AM Eastern

About Tissue Regenix Group Stock (LON:TRX)

Advanced

Key Stats

Today's Range
8.50
8.74
50-Day Range
7.70
32
52-Week Range
4.77
66
Volume
1.77 million shs
Average Volume
166,676 shs
Market Capitalization
£6.23 million
P/E Ratio
N/A
Dividend Yield
4.12%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive TRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tissue Regenix Group and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TRX Stock News Headlines

Tissue Regenix Scraps Sale Plans, Flags Profit Ahead
Shots officially fired…
Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the rights to deliver direct-to-cell service nationwide — a move tech analyst Jeff Brown says could shape the backbone of the coming space economy and create fortunes on a scale not seen since the rise of NVIDIA.tc pixel
Tissue Regenix Group Regulatory News
Tissue Regenix Group Share Chat (TRX)
Tissue Regenix Group PLC (LSW.BE)
See More Headlines

TRX Stock Analysis - Frequently Asked Questions

Tissue Regenix Group's stock was trading at GBX 60 at the start of the year. Since then, TRX shares have decreased by 85.4% and is now trading at GBX 8.74.

Tissue Regenix Group plc (LON:TRX) issued its quarterly earnings results on Wednesday, September, 2nd. The company reported ($0.16) EPS for the quarter. Tissue Regenix Group had a negative net margin of 3.46% and a negative trailing twelve-month return on equity of 2.87%.

Shares of TRX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Based on aggregate information from My MarketBeat watchlists, some other companies that Tissue Regenix Group investors own include Lloyds Banking Group (LLOY), Argos Therapeutics (ARGSQ), FuelCell Energy (FCEL), TransEnterix (TRXDW), Swedbank (SWDBY), Trevena (TRVN) and Barrick Gold (ABX).

Company Calendar

Last Earnings
9/02/2020
Today
10/16/2025

Industry, Sector and Symbol

Stock Exchange
LON
Sector
Medical
Industry
Biotechnology
Sub-Industry
Precious Metals
Current Symbol
LON:TRX
CIK
N/A
Fax
N/A
Employees
120
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
GBX (0.02)
Trailing P/E Ratio
N/A
Forward P/E Ratio
17.92
P/E Growth
N/A
Net Income
-£1.11 million
Net Margins
-3.46%
Pretax Margin
N/A
Return on Equity
-2.87%
Return on Assets
0.50%

Debt

Debt-to-Equity Ratio
31.16
Current Ratio
4.03
Quick Ratio
2.36

Sales & Book Value

Annual Sales
£27.75 million
Price / Sales
0.23
Cash Flow
GBX 1.58 per share
Price / Cash Flow
5.70
Book Value
GBX 41.58 per share
Price / Book
0.22

Miscellaneous

Outstanding Shares
71,235,000
Free Float
N/A
Market Cap
£6.41 million
Optionable
Not Optionable
Beta
1.61
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (LON:TRX) was last updated on 10/17/2025 by MarketBeat.com Staff
From Our Partners